ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLF

Recruiting now · Not applicable

Conditions studied: Acute Liver Failure

In brief

The artificial liver support system (ALSS) in patients with acute on chronic liver failure - the use of combined molecular adsorption system with double plasma (DPMAS) and therapeutic plasma exchange (TPE), its effect on primary coagulation, inflammation and the function of vital organs.

Key facts

Study ID

NCT07329036

Run by

Institute for Clinical and Experimental Medicine

People needed

25

Starts

2024-04-01

Expected to finish

2026-12-31

Last updated by the study team

2026-01-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patient, age ≥18 years
• Expressed consent to the inclusion
• Patient hospitalized on ICU with ALF or ACLF diagnosis
• Recently meeting the inclusion to liver transplantation
• Present on a waiting list to liver transplant
• Unsuitable for inclusion to liver transplantation - indicated for support therapy only, but not indented to palliative care

You may not qualify if…

• Disagreement with the study
• Infaust prognosis with expected survival less than 24 hours
• Physiologically/biologically very advanced stage patients condition, severe lung disease (Gold criteria 3 or 4), heart failure (functional class NYHA III or IV) or neurological disease, as well as ACLF-3.
• Advanced oncological disease (expected life expectancy below 6 months)
• Severe degree of Frailty syndrome in secondary severe sarcopenia (muscle and malnutrition) or reduced performance state according

Where it is running

• Institute for Clinical and Experimental Medicine (IKEM) — Prague, Czechia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.